Status:
RECRUITING
A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.
Lead Sponsor:
Qianfoshan Hospital
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
18+ years
Brief Summary
To evaluate the effectiveness of TACE combined with immunotherapy and targeted therapy versus TACE alone in patients with intermediate and advanced liver cancer.
Detailed Description
To evaluate the efficacy and safety of TACE combined with immunotherapy and targeted therapy in patients with intermediate and advanced liver cancer. Explore the factors affecting the prognosis of liv...
Eligibility Criteria
Inclusion
- ≥18 years old, both men and women
- primary liver cancer confirmed by liver biopsy or history of hepatitis B, AFP, and typical imaging findings
- patients with liver function Child-Pugh A or B (≤8 points)
- BCLC stage B and stage C
- expected survival time ≥8 weeks
- patients with generally good performance status (ECOG PS score 0 or 1)
Exclusion
- The patient's key data is missing
- liver metastatic cancer confirmed by histology or cytology
- patients who interrupt treatment due to intolerance of adverse drug reactions
- combined with primary malignant tumors of other organs within 5 years; combined with other serious diseases, such as severe heart disease, renal insufficiency, severe infection, bleeding, etc.
- combined with systemic infection, autoimmune disease, or other types of tumors; previous allogeneic bone marrow transplantation or solid organ transplantation
- study participants known to have mental illness
- situations such as drug use or substance abuse
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06205732
Start Date
January 1 2024
End Date
December 1 2024
Last Update
January 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the Qianfoshan Hospital
Jinan, Shandong, China, 250000